| Authors: |
Stacchiotti S; Medical Oncology Unit 2, Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Martini S; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Pasquali S; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Frezza AM; Medical Oncology Unit 2, Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Beretta A; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Percio S; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Lecchi M; Unit of Bioinformatics and Biostatistics, Department Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tortoreto M; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Barisella M; Pathology Unit, ASST Fatebenefratelli Sacco, Milan, Italy., Collini P; Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Dagrada GP; Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Merlini A; Department of Oncology, University of Turin, Turin, Italy., Huang PH; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom., Jenks A; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom., Jones RL; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Tap WD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Ingrosso M; Medical Oncology Unit 2, Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Morosi C; Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Brich S; Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Giani C; Medical Oncology Unit 2, Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Verderio P; Unit of Bioinformatics and Biostatistics, Department Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Casali PG; Medical Oncology Unit 2, Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Leonard H; Chair of Trustees of the EHE Rare Cancer Charity UK, Charity Number 1162472, Kingston-Upon-Thames, United Kingdom., Gronchi A; Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Zuco V; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Zaffaroni N; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. |
